Abstract
Objective
The purpose of this study was to assess the clinical application value of bone turnover markers in non-small-cell lung cancer (NSCLC) patients with bone metastases. Including diagnosing bone metastases, detecting bone metastatic spread.
Methods
Alkaline phosphatase (AKP), β-C-terminal telopeptide of type I collagen (β-CTx), osteocalcin (OST) and bone alkaline phosphatase (BALP) were measured in 76 patients with bone metastases from NSCLC and 44 normal people.
Results
The level of AKP, β-CTx and BALP in patients with bone metastasis was significantly higher than in the normal people. Significant correlation was observed among bone turnover markers. The levels of BALP and OST were significantly correlated with the extent of bone metastasis. The patients with high-level CTx and low-level BALP had higher risk of pathologic fracture.
Conclusion
In NSCLC patients with bone metastases, bone turnover markers can help to make diagnosis and evaluate the severity. It will have a wide range of use in clinical practice.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Rodoman GD. Mechnaisms of bone metastasis. N Engl J Med, 2004, 350: 1655–1664.
Ebert W, Muley T. Comparison of bone scintigraphy with bone markers in the diagnosis of bone metastasis in lung carcinoma patients. Anticancer Res, 2004, 24: 3193–3201.
Alatas F, Alatas O, Metintas M. Usefulness of bone markers for detection of bone metastases in lung cancer patients. Clin Biochem, 2002, 35: 293–296.
Koizumi M, Takahashi S, Ogata E. Bone metabolic markers in bisphosphonate therapy for skeletal metastases in patients with breast cancer. Breast Cancer, 2003, 10: 21–27.
Berruti A, Dogliotti L, Gorzegno G, et al. Differential patterns of bone turnover in relation to bone pain and disease extent in bone in cancer patients with skeletal metastases. Clin Chem, 1999, 45: 1240–1247.
Terpos E, Kiagia M, Karapanagiotou EM, et al. The clinical significance of serum markers of bone turnover in NSCLC patients: surveillance, management and prognostic implications. Anticancer Res, 2009, 29: 1651–1658.
Shimozuma K, Sonoo H, Fukunaga M, et al. Biochemical markers of bone turnover in breast cancer patents with bone metastases: A preliminary report. Jpn J Clin Oncol, 1999, 29: 16–22.
Yu J, Di LJ, Wan FL, et al. The clinical significance of bone metabolism biochemical markers in diagnosis of bone metastasis. Chin J Clin Oncol (Chinese), 2005, 32: 1193–1196.
Clarke NW, McClure J, George NJ. Morphometric evidence for bone resorption and replacement in prostate cancer. Br J Urol, 1991, 68: 74–80.
Yin JJ, Pollock CB, Kelly K. Mechanisms of cancer metastasis to the bone. Cell Res, 2005, 15: 57–62.
Yin JJ, Mohammad KS, Kakonen SM, et al. A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases. Proc Natl Acad Sci USA, 2003, 100: 10954–10959.
Allen JD, van Loevezijn A, Lakhai JM, et al. Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C. Mol Cancer Ther, 2002, 1: 417–425.
Brown JE, Cook RJ, Major P, et al. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst, 2005, 97: 59–69.
Author information
Authors and Affiliations
Corresponding author
Additional information
Supported by grants from the Foundation of Shanghai Shenkang Hospital Development Centre (No. SHDC12007304) and Shanghai Public Health Bureau (No. 2009086).
Rights and permissions
About this article
Cite this article
Wang, Z., Yang, C., Yang, Y. et al. Clinical application value of bone turnover markers in non-small-cell lung cancer patients with bone metastases. Chin. -Ger. J. Clin. Oncol. 10, 81–84 (2011). https://doi.org/10.1007/s10330-011-0729-3
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10330-011-0729-3